Systemic therapy using bone-seeking radiopharmaceuticals has clear advantages for the
treatment of multisite metastatic pain. Evidence supporting the use of β-particle, electron …

Bone metastasis develops in multiple malignancies with a wide range of incidence. The
presence of multiple bone metastases, leading to a multitude of complications and poorer …

Background Pain from skeletal metastases represents a major burden of advanced disease
from solid tumors. Analgesic medications, bisphosphonates, hormonal agents, cytotoxic …

Bone metastasis is a common sequella of solid malignant tumors such as prostate, breast,
lung, and renal cancers, which can lead to various complications, including fractures …

Pain in patients with cancer metastatic to bone is a significant cause of morbidity and of
referrals from general practice and specialist physicians. Management typically utilizes …

Introduction Bone pain is a common symptom of metastatic disease in cancer, experienced
with various intensities by about 30% of cancer patients, during the development of their …

Food and Drug Administration for palliation of metastatic bone pain (10— 15). Despite the
use of 32Pin large numbers of patients over many years (Table 1), there is a great …

Purpose: Intractable bone pain secondary to bone metastasis from prostate, lung, breast,
and other malignancies is a major problem in the management of the oncological patient …

Pain palliation with bone-seeking radiopharmaceuticals is an effective and cost-effective
management tool in patients with advanced cancer metastatic to bone. Strontium-89 …

A variety of radiopharmaceuticals has been used for systemic therapy to reliee pain from
malignancies metastatic to bone, using electron emitting radionuclides either in ionic form or …